Horizon Therapeutics PLC (NASDAQ:HZNP)’s share price traded up 8.7% during trading on Tuesday . The stock traded as high as $27.60 and last traded at $27.03, 1,910,467 shares traded hands during trading. An increase of 13% from the average session volume of 1,685,674 shares. The stock had previously closed at $24.87.

Several equities research analysts have recently issued reports on HZNP shares. BidaskClub lowered shares of Horizon Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 13th. Goldman Sachs Group began coverage on shares of Horizon Therapeutics in a research note on Wednesday, January 8th. They issued a “neutral” rating and a $35.00 price objective for the company. Stifel Nicolaus lifted their price objective on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Bank of America reduced their price objective on shares of Horizon Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Monday. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $49.00 price objective (up from $36.00) on shares of Horizon Therapeutics in a research note on Tuesday, December 24th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $38.14.

The business’s 50-day moving average price is $32.87 and its 200 day moving average price is $31.83. The stock has a market capitalization of $5.14 billion, a PE ratio of 10.43, a price-to-earnings-growth ratio of 0.97 and a beta of 0.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.26 and a current ratio of 2.33.

Horizon Therapeutics (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.14. The firm had revenue of $363.50 million during the quarter, compared to analyst estimates of $349.25 million. Horizon Therapeutics had a net margin of 44.08% and a return on equity of 23.07%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.67 EPS. As a group, equities research analysts predict that Horizon Therapeutics PLC will post 1.89 earnings per share for the current year.

In other news, EVP Vikram Karnani sold 9,297 shares of Horizon Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $35.62, for a total transaction of $331,159.14. Following the completion of the sale, the executive vice president now directly owns 92,654 shares of the company’s stock, valued at approximately $3,300,335.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Timothy P. Walbert sold 93,864 shares of Horizon Therapeutics stock in a transaction on Friday, February 21st. The stock was sold at an average price of $35.23, for a total transaction of $3,306,828.72. Following the sale, the chief executive officer now directly owns 963,064 shares of the company’s stock, valued at $33,928,744.72. The disclosure for this sale can be found here. Insiders have sold a total of 192,592 shares of company stock valued at $6,821,115 over the last ninety days. 4.30% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of HZNP. Point72 Hong Kong Ltd bought a new stake in shares of Horizon Therapeutics during the 4th quarter worth $37,000. IFP Advisors Inc grew its holdings in Horizon Therapeutics by 163.0% in the fourth quarter. IFP Advisors Inc now owns 1,086 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 673 shares during the period. Fred Alger Management LLC purchased a new stake in Horizon Therapeutics in the fourth quarter worth about $109,000. Penserra Capital Management LLC purchased a new stake in Horizon Therapeutics in the fourth quarter worth about $155,000. Finally, Contravisory Investment Management Inc. purchased a new stake in Horizon Therapeutics in the fourth quarter worth about $171,000. 89.69% of the stock is owned by institutional investors.

About Horizon Therapeutics (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Recommended Story: What is a Candlestick Chart?

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.